In a phase 2 trial of a novel antihypertensive agent, multiple doses lowered plasma angiotensinogen to a greater extent than a single dose, but did not provide further blood pressure lowering, ...
The Phase 2b SEISMiC Extension Study showed istaroxime significantly improved systolic blood pressure over six hours compared to placebo. Windtree plans to present detailed study findings, including ...
WILMINGTON, Del.--(BUSINESS WIRE)--Positive full results from the BaxHTN Phase III trial showed baxdrostat demonstrated a statistically significant and clinically meaningful reduction in mean seated ...
Among individuals with cardiovascular disease or high cardiovascular risk and uncontrolled hypertension on multiple anti-hypertensive agents, a single subcutaneous dose of zilebesiran 300 mg led to a ...
*The main analyses of ambulatory BP endpoints include patients with valid ambulatory blood pressure monitoring at both baseline and Week 12, without imputation of missing data. The Phase III Bax24 ...
Baxdrostat 2mg lowered systolic blood pressure by 15.7 mmHg (9.8 mmHg placebo-adjusted) from baseline, and was generally well tolerated with no unanticipated safety findings Full results presented at ...
WILMINGTON, Del.--(BUSINESS WIRE)-- Positive full results from the Bax24 Phase III trial showed baxdrostat demonstrated a statistically significant and highly clinically meaningful reduction in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results